Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Twitter
Vivo
Chitra Ramkrishna
Stock Market
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Business News / GSK recalls popular antacid Zinetac amid concerns over cancer-causing substance
Business

GSK recalls popular antacid Zinetac amid concerns over cancer-causing substance

GSK recalls popular antacid Zinetac amid concerns over cancer-causing substance
Written by Siddhant Pandey
Sep 26, 2019, 01:48 pm 3 min read
GSK recalls popular antacid Zinetac amid concerns over cancer-causing substance

Amid an ongoing probe into Ranitidine's reported cancer-causing impurities, GlaxoSmithKline Pharmaceuticals Limited (GSK) has recalled Ranitidine-based antacid Zinetac (150mg and 300mg) in India and other markets. Reportedly, Zinetac is the second-largest brand of acidity and heartburn medicine in India. After the company recalled Zinetac, shares of the British drugmaker dropped by 5% in early trade on Thursday. Here are more details.

Details
GSK had announced Ranitidine recall on Wednesday

Notably, on Wednesday, GSK had announced that it would suspend the release, distribution and supply of all dose forms of Ranitidine Hydrochloride products to all markets, including India. The decision followed the ongoing US Food and Drug Administration investigation after the detection of genotoxic nitrosamine NDMA impurities in Ranitidine products.

Probe
After US FDA's alert, DCGI demanded verification of drug's safety

Recently, the US FDA had alerted healthcare professionals across the globe about a voluntary recall of Ranitidine drugs by American pharmaceutical company Sandoz Inc. The recall was issued over the presence of N-nitrosodimethylamine (NDMA) impurities, which is classified as a probable human carcinogen. Thereafter, the Drugs Controller General of India (DCGI) directed state regulators to verify the safety of the antacid.

Quote
GSK to continue investigations into potential NDMA source

In response to DGCI, GSK noted that it "is continuing with investigations into the potential source of the NDMA. These investigations include continued engagement with our API suppliers. Patient safety remains the company's utmost priority and we are taking this issue very seriously."

Recall
GSK recalled Zinetac manufactured using Ranitidine Hydrochloride from Saraca Labs

Now, GSK manufactures Ranitidine Hydrochloride IP Tablets 150 mg and 300 mg (Zinetac) using active pharmaceutical ingredient (API) from two suppliers: Saraca Laboratories Limited and SMS Lifesciences India Limited. The European Directorate for V Quality of Medicines had notified Saraca Laboratories that its certificate of suitability for Ranitidine Hydrochloride had been suspended. Consequently, GSK decided to recall Zinetac manufactured using API from Saraca Laboratories.

Quote
Recall doesn't extend to products manufactured using SMS Lifesciences API

GSK added, "Product manufactured using API from SMS Lifesciences India Limited will not be recalled at this point of time. However, all such products will remain on hold and they will not be released to the market while the Company will await the test results."

Ranitidine
Ranitidine has massive Rs. 700cr market in India

Notably, Ranitidine is a widely-sold antacid, which has a market size of Rs. 688.6 crore in India, The Economic Times reported, citing data shared by AIOCD PharmaTrac. The drug is commonly prescribed to reduce the amount of acid created by the stomach. In India, several companies sell Ranitidine-based drugs including JB Chemicals, Cadila Pharma, Zydus Cadila, Dr Reddy's and Sun Pharmaceuticals, apart from GSK.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Siddhant Pandey
Siddhant Pandey
Twitter
Siddhant Pandey covers national and health news at NewsBytes. He has over five years of experience working as a multimedia journalist covering hard news in New Delhi. He was previously employed with The Indian Express and News World India and has juggled roles as a correspondent, copy editor, and video producer. He holds a Bachelor’s degree in Biotechnology from the Jaypee Institute of Information Technology, Noida.
Latest
India
National Disaster Management Authority
GlaxoSmithKline
Drugs Controller General of India
Zydus Cadila
Related
Latest
Redmi Note 11SE debuts with MediaTek Dimensity 700 SoC
Redmi Note 11SE debuts with MediaTek Dimensity 700 SoC Technology
Top 5 biographical movies that Hollywood has churned out
Top 5 biographical movies that Hollywood has churned out Entertainment
AS Roma win UEFA Europa Conference League title: Records broken
AS Roma win UEFA Europa Conference League title: Records broken Sports
2023 Honda CR-V previewed with hybrid badge ahead of debut
2023 Honda CR-V previewed with hybrid badge ahead of debut Auto
Five most tone-deaf things said by Hollywood celebrities
Five most tone-deaf things said by Hollywood celebrities Entertainment
India
Centre reconstitutes Inter-State Council; Modi to be chairman: Details here
Centre reconstitutes Inter-State Council; Modi to be chairman: Details here India
Monkeypox: Maharashtra, Tamil Nadu, Rajasthan prepare to fight against virus
Monkeypox: Maharashtra, Tamil Nadu, Rajasthan prepare to fight against virus India
PM Modi meets Japanese IT giant head, discusses investment opportunities
PM Modi meets Japanese IT giant head, discusses investment opportunities World
Pakistan commits to fighting terrorism, seeks 'balanced ties' with world
Pakistan commits to fighting terrorism, seeks 'balanced ties' with world World
10,000 people stuck as Rishikesh-Yamunotri Highway safety wall collapses
10,000 people stuck as Rishikesh-Yamunotri Highway safety wall collapses India
More News
National Disaster Management Authority
Assam floods: 4 more deaths take death toll to 18
Assam floods: 4 more deaths take death toll to 18 India
TN: 4 workers trapped in stone quarry, rescue operation underway
TN: 4 workers trapped in stone quarry, rescue operation underway India
Heatwave: Experts suggest COVID-like surveillance for old, vulnerable people
Heatwave: Experts suggest COVID-like surveillance for old, vulnerable people India
COVID-19 death compensation: SC fixes timelines for filing of claims
COVID-19 death compensation: SC fixes timelines for filing of claims India
Centre seeks extension for ex-gratia compensation to COVID-19 victims' kin
Centre seeks extension for ex-gratia compensation to COVID-19 victims' kin India
More News
GlaxoSmithKline
Sanofi-GSK vaccine candidate shows promising results
Sanofi-GSK vaccine candidate shows promising results World
COVID-19 vaccine: What are the latest updates?
COVID-19 vaccine: What are the latest updates? Technology
Artificial intelligence will aid in inventing drugs faster: Pharma companies
Artificial intelligence will aid in inventing drugs faster: Pharma companies Technology
GSK's first woman CEO to get 25% less than predecessor
GSK's first woman CEO to get 25% less than predecessor Business
Anti-malaria drug to hit Indian markets by 2018
Anti-malaria drug to hit Indian markets by 2018 India
More News
Drugs Controller General of India
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years India
COVAXIN likely to get approval for children above 2yrs: Report
COVAXIN likely to get approval for children above 2yrs: Report India
Biological E's Corbevax vaccine approved for children aged 12-18 years
Biological E's Corbevax vaccine approved for children aged 12-18 years India
COVAXIN, Covishield will now be available in hospitals and clinics
COVAXIN, Covishield will now be available in hospitals and clinics India
New anti-COVID drug may cost up to Rs. 3,000: Report
New anti-COVID drug may cost up to Rs. 3,000: Report India
More News
Zydus Cadila
Are Indian vaccines effective against Omicron? Here's what manufacturers say
Are Indian vaccines effective against Omicron? Here's what manufacturers say India
ZyCoV-D expected to be rolled out in two weeks: Report
ZyCoV-D expected to be rolled out in two weeks: Report India
Here are some key drugs being tested for COVID-19 treatment
Here are some key drugs being tested for COVID-19 treatment World
NTAGI to devise roadmap to introduce ZyCoV-D into inoculation drive
NTAGI to devise roadmap to introduce ZyCoV-D into inoculation drive India
COVID-19 vaccine trials for ages 3-12 soon: Zydus Cadila MD
COVID-19 vaccine trials for ages 3-12 soon: Zydus Cadila MD India
More News
Related
How does Merck's new COVID-19 drug work?
How does Merck's new COVID-19 drug work? Technology
Next News Article
Next News Article

Love Business news?

Subscribe to stay updated.

Business Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022